Emerald Health Preparing for Phase 2 Trial of EHP-101 for Relapsing MS 4.3 (12) Emerald Health Pharmaceuticals (EHP) is preparing for an international Phase 2 clinical trial testing EHP-101 for the treatment of multiple sclerosis (MS). The study will take place in about 20 locations in the U.S. and Australia, and is expected to include approximately 50 patients with relapsing forms of MS — relapsing-remitting and relapsing secondary progressive MS. Enrollment is expected to begin later this year. “The initiation of this MS Phase 2 study is another important milestone for our lead product candidate, EHP-101,” Joachim Schupp, MD, EHP’s chief medical officer, said in a press release.